WO2001043733A2 - Compositions, trousses, appareil et procedes utiles pour inhiber l'inflammation cephalique - Google Patents

Compositions, trousses, appareil et procedes utiles pour inhiber l'inflammation cephalique Download PDF

Info

Publication number
WO2001043733A2
WO2001043733A2 PCT/US2000/033916 US0033916W WO0143733A2 WO 2001043733 A2 WO2001043733 A2 WO 2001043733A2 US 0033916 W US0033916 W US 0033916W WO 0143733 A2 WO0143733 A2 WO 0143733A2
Authority
WO
WIPO (PCT)
Prior art keywords
local anesthetic
patient
headache
administration
long
Prior art date
Application number
PCT/US2000/033916
Other languages
English (en)
Other versions
WO2001043733A3 (fr
Inventor
Bruce H. Levin
Original Assignee
Levin Bruce H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levin Bruce H filed Critical Levin Bruce H
Priority to AU21009/01A priority Critical patent/AU2100901A/en
Publication of WO2001043733A2 publication Critical patent/WO2001043733A2/fr
Publication of WO2001043733A3 publication Critical patent/WO2001043733A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/075—Bulb type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés, des trousses, un appareil et des compositions utilisés pour inhiber l'inflammation céphalique y compris l'inflammation méningée et l'inflammation cérébrale par exemple, chez un patient humain. Les procédés consistent à administrer au patient par voie intranasale une composition pharmaceutique renfermant un anesthésique local et de préférence un ingrédient anesthésique local à action prolongée. On décrit une composition utile pour mettre en oeuvre les procédés selon l'invention qui comprend au moins un anesthésique local incorporé dans un support pharmaceutiquement acceptable, ladite composition étant formulée pour l'administration par voie intranasale. Une trousse contenant la composition et l'applicateur intranasal est également présentée dans l'invention ainsi qu'un appareil permettant de distribuer ou d'appliquer les compositions selon l'invention ou de mettre en oeuvre les procédés selon l'invention.
PCT/US2000/033916 1999-12-15 2000-12-15 Compositions, trousses, appareil et procedes utiles pour inhiber l'inflammation cephalique WO2001043733A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21009/01A AU2100901A (en) 1999-12-15 2000-12-15 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17081799P 1999-12-15 1999-12-15
US60/170,817 1999-12-15

Publications (2)

Publication Number Publication Date
WO2001043733A2 true WO2001043733A2 (fr) 2001-06-21
WO2001043733A3 WO2001043733A3 (fr) 2002-05-10

Family

ID=22621377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033916 WO2001043733A2 (fr) 1999-12-15 2000-12-15 Compositions, trousses, appareil et procedes utiles pour inhiber l'inflammation cephalique

Country Status (2)

Country Link
AU (1) AU2100901A (fr)
WO (1) WO2001043733A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108141A2 (fr) * 2003-06-04 2004-12-16 Paradigm Therapeutics Limited Utilisation de composes en medecine
US6853858B2 (en) 2000-05-08 2005-02-08 Brainsgate, Ltd. Administration of anti-inflammatory drugs into the central nervous system
DE10358749A1 (de) * 2003-12-12 2005-07-14 Lts Lohmann Therapie-Systeme Ag Darreichungsform zur Bekämpfung von primären Kopfschmerzen
EP1754510A1 (fr) 2005-08-19 2007-02-21 Brainsgate Ltd. Stimulation pour le traitement d'événements cérébraux et d'autres conditions
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US7908000B2 (en) 2004-02-20 2011-03-15 Brainsgate Ltd. Transmucosal electrical stimulation
ITTO20110576A1 (it) * 2011-06-30 2012-12-31 Medicam Health Science S R L Composizione comprendente l'associazione di fitoestratto di melissa, metilammide ed una fonte di nucleotidi e/o nucleosidi e suo impiego nel trattamento di cefalee ed emicranie
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
WO2017171681A1 (fr) * 2016-03-30 2017-10-05 Endemesis Ilac Sanayi Ve Ticaret A. S. Utilisation d'une composition qui contient un anesthésique local pour traiter la nausée
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
WO2024023676A1 (fr) * 2022-07-28 2024-02-01 Cochlear Limited Techniques d'administration d'un stimulus pour le traitement des acouphènes

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0754453A1 (fr) * 1995-07-17 1997-01-22 Rainer K. Dr. Liedtke Application topique d'anesthétiques locaux pour traiter les maux de tête
BE1009851A3 (fr) * 1996-01-11 1997-10-07 Thiebauld Charles Marie Composition pharmaceutique pour le traitement des cephalees et son utilisation.
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
WO1998038998A1 (fr) * 1997-03-03 1998-09-11 Darwin Discovery Limited Utilisation de la levobupivacaine ou de la ropivacaine dans le traitement de la migraine
WO1999003473A1 (fr) * 1997-07-21 1999-01-28 Astra Aktiebolag Compositions, kits et procedes permettant d'inhiber des troubles cerebraux neurovasculaires et des cephalees musculaires
WO1999032103A1 (fr) * 1997-12-19 1999-07-01 Astrazeneca Ab Nouvelle utilisation d'anesthesiants locaux pour traiter les cephalees vasculaires
WO2000044432A1 (fr) * 1999-01-27 2000-08-03 Levin Bruce H Compositions, kits, appareil et methodes d'inhibition des troubles cerebraux neurovasculaires et des cephalees musculaires

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0754453A1 (fr) * 1995-07-17 1997-01-22 Rainer K. Dr. Liedtke Application topique d'anesthétiques locaux pour traiter les maux de tête
BE1009851A3 (fr) * 1996-01-11 1997-10-07 Thiebauld Charles Marie Composition pharmaceutique pour le traitement des cephalees et son utilisation.
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
WO1998038998A1 (fr) * 1997-03-03 1998-09-11 Darwin Discovery Limited Utilisation de la levobupivacaine ou de la ropivacaine dans le traitement de la migraine
WO1999003473A1 (fr) * 1997-07-21 1999-01-28 Astra Aktiebolag Compositions, kits et procedes permettant d'inhiber des troubles cerebraux neurovasculaires et des cephalees musculaires
WO1999032103A1 (fr) * 1997-12-19 1999-07-01 Astrazeneca Ab Nouvelle utilisation d'anesthesiants locaux pour traiter les cephalees vasculaires
WO2000044432A1 (fr) * 1999-01-27 2000-08-03 Levin Bruce H Compositions, kits, appareil et methodes d'inhibition des troubles cerebraux neurovasculaires et des cephalees musculaires

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"THE MERCK MANUAL" 1999 , MERCK RESEARCH LABORATORIES XP002181662 page 1376 -page 1377 *
C.A. CAPUTI ET AL.: "Therapeutic Blockage of Greater Occipital and Supraorbital Nerves in Migraine Patients" HEADACHE, vol. 37, no. 3, 1997, pages 174-179, XP001036584 *
KUDROW L ET AL: "Rapid and sustained relief of migraine attacks with intranasal lidocaine: preliminary findings" HEADACHE, AMERICAN ASSOCIATION FOR THE STUDY OF HEADACHE,, US, vol. 35, no. 2, 1 February 1995 (1995-02-01), pages 79-82, XP002086202 ISSN: 0017-8748 *
MAIZELS M ET AL: "Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial Äsee commentsÜ" JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, CHICAGO,IL, US, vol. 276, no. 4, 24 July 1996 (1996-07-24), pages 319-321, XP002086201 ISSN: 0098-7484 *
PAPPAGALLO, MARCO (1) ET AL: "Imaging neurogenic inflammation in patients with migraine headaches." NEUROLOGY, (APRIL 12, 1999) VOL. 52, NO. 6 SUPPL. 2, PP. A274-A275. MEETING INFO.: 51ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY TORONTO, ONTARIO, CANADA APRIL 17-24, 1999 AMERICAN ACADEMY OF NEUROLOGY. , XP001036585 cited in the application *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6853858B2 (en) 2000-05-08 2005-02-08 Brainsgate, Ltd. Administration of anti-inflammatory drugs into the central nervous system
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
WO2004108141A3 (fr) * 2003-06-04 2005-03-31 Paradigm Therapeutics Ltd Utilisation de composes en medecine
WO2004108141A2 (fr) * 2003-06-04 2004-12-16 Paradigm Therapeutics Limited Utilisation de composes en medecine
US7998503B2 (en) 2003-12-12 2011-08-16 Lts Lohmann Therapie-Systeme Ag Form of administration for controlling primary headaches
DE10358749A1 (de) * 2003-12-12 2005-07-14 Lts Lohmann Therapie-Systeme Ag Darreichungsform zur Bekämpfung von primären Kopfschmerzen
US8954149B2 (en) 2004-02-20 2015-02-10 Brainsgate Ltd. External stimulation of the SPG
US7908000B2 (en) 2004-02-20 2011-03-15 Brainsgate Ltd. Transmucosal electrical stimulation
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
EP1754510A1 (fr) 2005-08-19 2007-02-21 Brainsgate Ltd. Stimulation pour le traitement d'événements cérébraux et d'autres conditions
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
ITTO20110576A1 (it) * 2011-06-30 2012-12-31 Medicam Health Science S R L Composizione comprendente l'associazione di fitoestratto di melissa, metilammide ed una fonte di nucleotidi e/o nucleosidi e suo impiego nel trattamento di cefalee ed emicranie
WO2013001509A1 (fr) 2011-06-30 2013-01-03 MEDICAM HEALTH SCIENCE S.r.l. Composition comprenant l'association d'un extrait de melissa officinalis, de méthylamide et de chaînes d'acide nucléique non codantes, et son utilisation dans le traitement de céphalées et de la migraine
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10512771B2 (en) 2013-11-10 2019-12-24 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
WO2017171681A1 (fr) * 2016-03-30 2017-10-05 Endemesis Ilac Sanayi Ve Ticaret A. S. Utilisation d'une composition qui contient un anesthésique local pour traiter la nausée
WO2024023676A1 (fr) * 2022-07-28 2024-02-01 Cochlear Limited Techniques d'administration d'un stimulus pour le traitement des acouphènes

Also Published As

Publication number Publication date
WO2001043733A3 (fr) 2002-05-10
AU2100901A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
US9302096B2 (en) Apparatus for treating cerebral neurovascular disorders including headaches by neural stimulation
US6491940B1 (en) Apparatus for administering composition for inhibiting cerebral neurovascular disorders and muscular headaches
US20010004644A1 (en) Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
US6432986B2 (en) Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20050281751A1 (en) Directed intranasal administration of pharmaceutical agents
US20160030408A1 (en) Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
EP0999839B1 (fr) Compositions, kits et procedes permettant d'inhiber des troubles cerebraux neuro-vasculaires et des cephaleees musculaires
ES2275229T3 (es) Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
JP6200648B2 (ja) 三叉神経・自律神経性頭痛、片頭痛、および血管症状の治療および予防のための組成物
WO2001043733A2 (fr) Compositions, trousses, appareil et procedes utiles pour inhiber l'inflammation cephalique
US20220152394A1 (en) Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
KR20120042729A (ko) 비강 투여를 위한 테트라카인 및 혈관수축제를 포함하는 치과용 마취제
WO1999032103A1 (fr) Nouvelle utilisation d'anesthesiants locaux pour traiter les cephalees vasculaires
MXPA00000705A (en) Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
Hosal et al. A rationale for the selection of nasal decongestants in lacrimal drainage surgery
CZ2000215A3 (cs) Kompozice, kity a způsoby pro inhibici cerebrálních neurovaskuiárních poruch a svalové bolestí hlavy
Skarda et al. Local anesthetics and regional analgesic techniques
KR20170102892A (ko) 테트라카인계 마취제
Steven Padilla Anesthesia for Dermatologic Surgery.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP